PREDICTING UNSUCCESSFUL ELECTRICAL CARDIOVERSION FOR ACUTE ATRIAL FIBRILLATION (FROM THE AF-CVS SCORE)

Document Type : Original Article

Authors

Department of Cardiology, Faculty of Medicine Al-Azhar University

Abstract

Background: Despite good progress in the management of patients with atrial fibrillation, this arrhythmia remains one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity in the world. Furthermore, the number of patients with AF is predicted to rise steeply in the coming years.
Objective: To validate a clinical risk stratification tool (AF-CVS score) for identifying patients at high risk for unsuccessful outcome after electrical cardio-version for acute AF.
Patients and Methods: The present study was a cohort study conducted between March 2018 and March 2019. We enrolled 100 consecutive patients admitted at Al-Hussain University, Al-Azhar University, presented with acute onset atrial fibrillation (AF) requiring direct current electro-version (DC electro-version). An informed consent obtained from every patient after full explanation of the research objectives and the purpose of this study.
Results: A binary logistic regression was run to evaluate AFCVS score as a predictor for the recurrence among the patients in the study population. There was homoscedasticity and normality of the residuals. The binary logistic regression model was statistically significant (χ2= 28.01, df 1, p= < 0.001) with insignificant Hosmer and Lemeshow test (p 0.114). AFCVS score was a significant predictor for the AF recurrence in the studied population (p < 0.001). The diagnostic efficacy and cut off point of AFCVS for prediction of AF recurrence in the studied sample was determined using a receiver operating characteristic curve (ROC) and the AFCVS score cut off point was 5 . The score showed 83.8% sensitivity, 68.3% Specificity, 87.8% negative predictive value, 60.8% positive predictive value and 74% accuracy.
Conclusion: Atrial fibrillation provokes important economic burden along with significant morbidity and mortality. Our study showed that the risk of unsuccessful outcome of ECV can be predicted using five simple clinical variables: A-- Age. F-- not First time AF. C-- Cardiac failure. V-- Vascular disease. S-- Short duration from previous AF (within 1 month before electrical cardio-version (ECV)).

Keywords

Main Subjects


PREDICTING UNSUCCESSFUL ELECTRICAL CARDIOVERSION FOR ACUTE ATRIAL FIBRILLATION (FROM THE AF-CVS SCORE)

By

Hamdi Sobhi Ramadan El-Adawi, Abd El-Halem Mohamed Abo El-Magd and Mansour Mohamed Sallam

Department of Cardiology, Faculty of Medicine Al-Azhar University

Corresponding author: Hamdi Sobhi Ramadan El-Adawi,

E-mail: hamdiramadan_99@gmail.com

ABSTRACT

Background: Despite good progress in the management of patients with atrial fibrillation, this arrhythmia remains one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity in the world. Furthermore, the number of patients with AF is predicted to rise steeply in the coming years.

Objective: To validate a clinical risk stratification tool (AF-CVS score) for identifying patients at high risk for unsuccessful outcome after electrical cardio-version for acute AF.

Patients and Methods: The present study was a cohort study conducted between March 2018 and March 2019. We enrolled 100 consecutive patients admitted at Al-Hussain University, Al-Azhar University, presented with acute onset atrial fibrillation (AF) requiring direct current electro-version (DC electro-version). An informed consent obtained from every patient after full explanation of the research objectives and the purpose of this study.

Results: A binary logistic regression was run to evaluate AFCVS score as a predictor for the recurrence among the patients in the study population. There was homoscedasticity and normality of the residuals. The binary logistic regression model was statistically significant (χ2= 28.01, df 1, p= < 0.001) with insignificant Hosmer and Lemeshow test (p 0.114). AFCVS score was a significant predictor for the AF recurrence in the studied population (p< 0.001). The diagnostic efficacy and cut off point of AFCVS for prediction of AF recurrence in the studied sample was determined using a receiver operating characteristic curve (ROC) and the AFCVS score cut off point was 5 . The score showed 83.8% sensitivity, 68.3% Specificity, 87.8% negative predictive value, 60.8% positive predictive value and 74% accuracy.

Conclusion: Atrial fibrillation provokes important economic burden along with significant morbidity and mortality. Our study showed that the risk of unsuccessful outcome of ECV can be predicted using five simple clinical variables: A-- Age. F-- not First time AF. C-- Cardiac failure. V-- Vascular disease. S-- Short duration from previous AF (within 1 month before electrical cardio-version (ECV)).

Keywords: Electrical Cardioversion, Acute Atrial Fibrillation, AF-CVS score.

 

 

INTRODUCTION

     Atrial fibrillation (AF) is the most commonly encountered arrhythmia in clinical practice. Aging populations coupled with improved outcomes for many chronic medical conditions has led to increases in AF diagnoses. AF is also known to be associated with an increased risk of adverse events such as transient ischemic attack, ischemic stroke, systemic embolism, and death (Amin et al., 2016).

     Atrial Fibrillation remains one of the major causes of stroke, heart failure, sudden death, and cardiovascular morbidity in the world (Kirchhof et al., 2016).

     Quality of life is impaired in AF patients independent of other cardiovascular conditions. About 10-40% of AF patients are hospitalized every year (Kotecha et al., 2014). About 20-30% of patients with an ischemic stroke are due to AF (Kishore et al., 2014). A growing number of patients with stroke are diagnosed with silent paroxysmal AF (Stewart et al., 2012).

     In 2010, the estimated numbers of men and women with AF worldwide were 20.9 million and 12.6 million, respectively, with higher incidence and prevalence rates in developed countries. Furthermore, the number of patients with AF is predicted to rise steeply in the coming years (Kirchhof et al., 2016).

     Synchronized direct current electrical cardio-version (ECV) quickly and effectively converts AF to sinus rhythm, and is the method of choice in severe haemodynamically compromised patients with new onset AF (Kirchhof et al., 2012). Severity of AF symptoms and patient preference should be considered when embarking on a strategy requiring serial cardio-version procedures (January et al., 2019).

     Although electrical cardio-version (ECV) is the standard treatment for acute AF, the identification of patients with increased risk of ECV failure or early AF recurrence is of importance for clinical decision making. However, limited studies have been carried out to establish an association between the clinical variables and the outcome of the ECV (Jaakkola et al., 2017).

     The aim of this study was to validate a clinical risk stratification tool (AF-CVS score) for identifying patients at high risk for unsuccessful outcome after electrical cardio-version for acute AF.

PATIENTS AND METHODS

     The present study was a cohort study conducted between March 2018 and March 2019. We enrolled 100 consecutive patients admitted at Al-Hussain University; Al-Azhar University presented with acute onset atrial fibrillation (AF) requiring direct current electro-version (DC electro-version). An informed consent was obtained from every patient after full explanation of the research objectives and the purpose of this study.

Inclusion Criteria: All patients with no contraindication for DC-Cardioversion were enrolled in the study:

•   Patients with acute onset first time AF aiming at restoring sinus rhythm.

•   Adult patients with documented paroxysmal AF assigned for rhythm control.

•   Patients with acute onset AF not responding to pharmacological therapy.

•   Patients with acute onset AF and pre-excitation with hemodynamic instability.

Exclusion Criteria:

•   Any patient refused to sign an informed consent.

•   All patients presented with AF who were assigned for rate control.

•   Valvular heart disease other than mild mitral and tricuspid valve regurgitation.

•   Rheumatic heart disease.

•   Previous heart valve surgery.

•   Congenital heart disease.

For each enrolled patient, the following data were collected:

History: Patients’ data as gender, age (in years), smoking status, presence or absence of hypertension, diabetes mellitus, ischemic heart disease, dyslipidemia, chronic obstructive airway disease and full drug history including alcohol consumption have been recorded. Detailed history of onset and duration of AF prior to DC cardio-version, previous DC cardio-version (type, joules and post complications) and the date of follow up after the DC cardio-version. From previous data, we calculated the AF-CVS score.

AF-CVS score:

     Identification of the risk of electrical cardio-version failure according to the clinical variables in the AF-CVS score which are:

A— Age: Age (years): 65 = 2 points.

F-- Not First time AF: Not the First AF episode = 2 points

C-- Cardiac failure: Cardiac failure = 2 points

1.  Patients with HFPEF: patients with symptoms and signs of congestive heart failures, left ventricular ejection fraction (LVEF) >50% and non a dilated left ventricle and evidence of elevated left ventricular filling pressure.

2.  Patients with HFREF: patients with impaired contractility of the left ventricle in an ejection fraction (EF) of <40% to 50%.

V-- Vascular disease: Vascular disease = 1 point

S-- Short duration from previous AF (within 1 month before electrical cardio-version (ECV)): Short interval (another AF episode within 30 days) = 3 points.

Basic examination: Clinical data as heart rate, systolic and diastolic blood pressures at rest were performed in details with: General examination, cardiac examination, weight (in Kilograms), height (in Centimeters) and body Mass Index (BMI) (in Kilograms/Square meters).

Laboratory assessment: Routine laboratory investigations were done as HBA1C, lipid profile, thyroid profile, liver function test, renal function test, and full blood picture as well as coagulation profile.

Imaging: ECG, echocardiography, chest X-ray and trans esophageal echo cardiography (TOE).

Intervention: Electrical Cardio-version

Patient preparation:

•   Review of: history & physical examination, medication & anticoagulation and thromboembolic risk.

•   12 lead ECG

•   Peripheral venous access

•   O2 airway

•   Sedation: midazolam 2mg over 2 minutes

Technique:

•   Electrodes placement: patches are placed in antero-apical position

•   Energy: 100 joule biphasic

•   Synchronization: synchronized

     Patients were followed up for 30 days after electrical cardio-version to record the symptoms, signs and persistence of sinus rhythm as well as DC-cardioversion outcome and evaluate the validity of the AF-CVS score in prediction.

Statistical analysis:

     Recorded data were analyzed using the statistical package for social sciences, version 20.0 (SPSS Inc., Chicago, Illinois, USA). Quantitative data were expressed as mean± standard deviation (SD). Qualitative data were expressed as frequency and percentage. Independent-samples t-test of significance was used when comparing between two means. Chi-square (x2) test of significance was used in order to compare proportions between two qualitative parameters. Mann-whitney U test was used to compare AFCVS score. A receiver operating characteristic curve (ROC) was used to determine the diagnostic efficacy and cut off points of AFCVS score. The confidence interval was set to 95% and the margin of error accepted was set to 5%. P < 0.05 was considered significant.


 

RESULTS

 

 

     Demographic data were presented in Table (1).

 

Table (1):   Patient demographics and medical history

 

All patients (n= 100)

 

Mean & SD

Median

Minimum

Maximum

IQR

Age (years)

51.97 ± 11.356

52.50

29

78

45.00, 59.50

Height (m)

1.68 ± 0.064

1.68

1.53

1.89

1.63, 1.72

Weight (kg)

86.73 ± 16.099

85.00

55.00

120.00

75.00, 99.75

BMI

30.84 ± 5.916

30.09

18.38

46.87

26.35, 34.23

Gender

Males

50% (50)

Females

50% (50)

Smoking

37% (37)

Alcohol

2% (2)

HTN

58% (58)

DM

46% (46)

IHD

46% (46)

COPD

13% (13)

OSA

13% (13)

Data were expressed as mean and standard deviation, median, Minimum, Maximum and Inter-quartile range or percentage and frequency.

 

 

     Patients’ age ranged from 29 to 78 years. 37% of them were smokers and 2% were alcoholics. Patient's height ranged from 1.53m to 1.89m. Patient’s weight ranged from 55kg to 120kg. Patient’s body mass index (BMI) ranged from 18.38 to 46.87. 58% of the patients were hypertensive 46% of the patients were diabetic 46% of the patients were ischemic heart disease 13% of the patients were chronic obstructive pulmonary disease 13% of the patients were obstructive sleep apnea (Table 2).

 

 

Table (2):   Comparison of demographic data and CVS risk factors between cases according to AF recurrence

Demographic Characteristics

No recurrence

(n= 63)

Recurrence

(n= 37)

t/ χ2#

p-value

Age (years)

Mean±SD

Range

 

50.41±9.73

(29.0-69.0)

 

57.35±13.70

(35.0-78.0)

2.95

0.004

Sex

Female

Male

 

35(55.6%)

28(44.4%)

 

15(40.5%)

22(59.5%)

2.10

0.147

BMI (kg/m2)

Mean±SD

Range

 

31.30±5.18

(21.2-44.1)

 

30.06±7.02

(18.4-46.9)

1.01

0.315

AFCVS score

Mean±SD

Range

 

3.46±2.29

(0.0-8.0)

 

6.03±2.11

(1.0-10.0)

5.56

0.001

Smoking

No

Yes

 

46(73.0%)

17(27.0%)

 

17(45.9%)

20(54.1%)

7.33

0.007

Alcohol

No

Yes

 

62(98.4%)

1(1.6%)

 

36(97.3%)

1(2.7%)

FET

 

P=0.70

Hypertension

 

 

 

 

No

Yes

40(63.5)

23(36.5)

9(24.3)

28(75.7)

14.31

<0.001

DM

-VE

+VE

 

30(47.6%)

33(52.4%)

 

24(64.9)

13(35.1)

 

2.79

 

0.095

IHD

 

 

 

 

No

Yes

38(60.3%)

25(39.7%)

16(43.2%)

21(56.8%)

2.74

0.098

x2: Chi-square test; FET :Fischer exact test

 

 

 

 

 

 

 

 

 

     There was a statistically significant difference in age between patients with no AF recurrence and patients with recurrence (p value < 0.05). The recurrence group has higher age than no recurrence group.

     The percentage of smokers in the AF recurrence group was significantly higher than no AF recurrence group (p value < 0.05)

     There was a significant difference between both groups regarding hypertension (p value < 0.05).  Percentage of hypertensive patients was higher than non-hypertensive in the recurrence group. There was a statistically significant difference (p value < 0.001) between AFCVS score value in the group with recurrent AF and group with non-recurrent AF (Table 3).

 

 

Table (3):   Comparison of drug history  and COPD & OSA between cases according to AF recurrence

Recurrence

 

Parameters

No recurrence (n= 63)

Recurrence

(n= 37)

χ2

p-value

Drug history:

ACEIs

 

22(34.9%)

 

16(43.2%)

 

0.685

 

0.408

ARBs

12(19.0%)

8(21.6%)

0.097

0.756

BBs

27(42.9%)

17(45.9%)

0.09

0.764

CCBs

9(14.3%)

3(8.1%)

0.842

0.359

Digoxin

4(6.3%)

4(10.8%)

FET

0.463

Statins

34(54.0%)

24(64.9%)

1.14

0.304

Propafenone

6(9.5%)

3(8.1%)

0.057

0.811

Sotalol

00

0

0

1

Amiodarone

4(6.3%)

3(8.1%)

FET

0.708

COPD

6(9.5%)

7(18.9%)

1.82

0.177

OSA

4(6.3%)

2(5.4%)

FET

0.845

 

 

     There was no statistically significant difference between recurrence and non-recurrence group regarding drug history (Table 4).

 

 

Table (4):   Comparison of echocardiography according to AF recurrence incidence

Recurrence

Parameters

No recurrence

(n= 63)

Recurrence

(n= 37)

t-test/χ2

p-value

LVEF (%).

Mean±SD

Range

 

59.09±6.99

(40.0-71.0)

 

55.65±7.56

(42.0-65.0)

2.31

0.023

RV dysfunction

9 (14.3%)

9 (24.3%)

1.59

0.207

LV size (cm).

Mean±SD

Range

 

3.27±0.38

(2.5-4.0)

 

3.29±0.387

2.6-4.0

0.177

0.860

RA size (cm).

Mean±SD

Range

 

2.11±0.47

(1.5-3.2)

 

2.24±0.54

(1.5-3.5)

1.23

0.224

t-Independent Sample t-test;

 

     There was a statistically significant difference in LVEF of both groups. The LVEF was significantly higher in no AF recurrence group (p value < 0.05) (Table 5).

 

 

Table (5):   CHA2DS2_VASC and HASBLED score in the studied patients

 

All patients (n= 100)

CHA2DS2_VASC

0

13.0% (13)

1

18.0% (18)

2

32.0% (32)

3

17.0% (17)

4

10.0% (10)

5

10.0% (10)

HASBLED

0

21.0% (21)

1

31.0% (31)

2

26.0% (26)

3

19.0% (19)

4

3.0% (3)

Data was expressed as percentage and frequency.

 

 

     A binary logistic regression was run to evaluate AFCVS score as a predictor for the recurrence among the patients in the study population. There was homoscedasticity and normality of the residuals. The binary logistic regression model was statistically significant (χ2= 28.01, df 1, p= < 0.001) with insignificant Hosmer and Lemeshow test (p 0.114). AFCVS score was a significant predictor for the AF recurrence in the studied population (p< 0.001). The model classified 63% of the studied sample with Nagelkerke R2 33.4% (Table 6).

 

 

Table (6):   ACCVS score for recurrence prediction

 

B

P

Odds ratio

95% CI

AFCVS

0.479

0.001

1.614

1.311, 1.987

 

 

     A receiver operating characteristic curve (ROC) was used to determine the diagnostic efficacy and cut off point of AFCVS for prediction of AF recurrence in the studied sample.

     The diagnostic efficacy and cut off point of AFCVS for prediction of AF recurrence in the studied sample was determined using a receiver operating characteristic curve (ROC) and the AFCVS score cut off point was 5. The score showed 83.8% sensitivity, 68.3% Specificity, 87.8% negative predictive value, 60.8% positive predictive value and 74% accuracy (Table 7 and Figure 1).

 

 

 

 

 

 

 

 

 

Table (7):   Diagnostic values of AFCVS score

Diagnostic values

AFCVS

Area under the curve

0.774

95% confidence interval

0.680, 0.868

Cut- off point

5 (rounded from 4.5)

Distance from the curve

0.13

Sensitivity

83.8%

Specificity

68.3%

Positive predictive value

60.8%

Negative predictive value

87.8%

Accuracy

74%

 
   

Figure (1):  ROC curve for AFCVS score

 

 

DISCUSSION

     We conducted our study on 100 cases of acute AF undergoing electric cardio-version either patients with acute AF to restore sinus rhythm or patients with acute AF not responding to pharmacological therapy or patients with acute AF and pre-excitation with hemodynamic instability.

     Patients’ age ranged from 29 to 78 years. 37% of them were smokers and 2% were alcoholics. Heeringa et al. (2010) study showed that current and former smoking of cigarettes was associated with increased risk of atrial fibrillation. Frost and Vestergaard (2010) found that consumption of alcohol was associated with an increased risk of atrial fibrillation.

     As regard hypertension, 58% of our patients were hypertensive. This is consistent with Kannel et al. (2010) who demonstrated that hypertension conferred a 1.5- and 1.4-fold risk for men and women, respectively after adjusting for other associated conditions.

     As regard diabetes mellitus, 46% of our patients were diabetic. This is consistent with Movahed et al. (2011) who demonstrated DM as a strong, independent risk for the occurrence of atrial fibrillation. Kannel et al. (2010) demonstrated that diabetes conferred a 1.4- and 1.6-fold risk for men and women, respectively after adjusting for other associated conditions.

     As regard IHD, 46% of patients had IHD. 13% of patients had COPD and as well 13% has OSA. Among the studied group 63% of patients showed no recurrence of AF while 37% showed recurrence. There was a statistically significant difference between AFCVS score value in the group with recurrent AF and group with non-recurrent AF. There was a statistically significant difference in age between patients with no AF recurrence and patients with recurrence. The recurrence group has higher age than no recurrence group in harmony with Lee et al. (2011) and Ma et al. (2011).

     There was a statistically significant difference in AFCVS score value of both groups. The group with AF recurrence has a higher score. The percentage of smokers in the AF recurrence group was significantly higher than no AF recurrence group in harmony with Kinoshita et al. (2010). There was a significant difference between both groups regarding hypertension. Percentage of hypertensive patients was higher than non-hypertensive in the recurrence group, in harmony with Berruezo et al. (2011).

     The value of HBA1c was significantly higher in AF recurrence group. The LVEF was significantly higher in no AF recurrence group. It was the first episode of AF in 31% of patients. Medical cardio-version was tried and failed in 56%. And it was the first time to have ECV in 74% of patients. Pharmacologic cardio-version is less effective, and time to conversion is unpredictable and may be relatively long according to Camm et al. (2011).

     There was a statistically significant difference between no recurrence and recurrence group regarding all the parameters of the AFCVS score. Age was higher in the recurrence group. The percentage of first AF episode was higher in no AF recurrence group. The presence of cardiac failure and vascular disease was higher in the recurrence group. The positive history of a short interval from last AF episode was significantly higher in recurrence group.

     A binary logistic regression was run to evaluate AFCVS score as a predictor for the recurrence among the patients in the study population. There was homoscedasticity and normality of the residuals. The binary logistic regression model was statistically significant with insignificant Hosmer and Lemeshow test. AFCVS score was a significant predictor for the AF recurrence in the studied population.

     The diagnostic efficacy and cut off point of AFCVS for prediction of AF recurrence in the studied sample was determined using a receiver operating characteristic curve (ROC) and the AFCVS score cut off point was 5. The score showed 83.8% sensitivity, 68.3% Specificity, 87.8% negative predictive value, 60.8% positive predictive value and 74% accuracy.

     In this study we have done another set of comparisons between cases according to the AFCVS score cut off point. The cutoff point 5 divided the cases into 2 groups: group 5 included 52 patients.

     The age and the presence of hypertension and IHD were significantly higher in patients with AFCVS score>5. The LVEF and level of HDL was significantly higher in patients with AFCVS score Heeringa et al. (2010).

CONCLUSION

     The risk of unsuccessful outcome of ECV can be predicted using five simple clinical variables: A-- Age. F-- Not First time AF. C-- Cardiac failure. V-- Vascular disease. S-- Short duration from previous AF (within 1 month before electrical cardio-version (ECV)). The AFCVS score has a 83.8% sensitivity and 74% accuracy.

REFERENCES

  1. Amin A, Houmsse A, Ishola A, Tyler J and Houmsse M. (2016): The current approach of atrial fibrillation management. Avicenna Journal of Medicine, 6(1):8-16.
  2. Berruezo A, Tamborero D, Mont L, Benito B and Tolosana JM. (2011): Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. European Heart Journal, 28(7): 836-841.
  3. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S and  Van Gelder IC (2011): Guidelines for the management of atrial fibrillation The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J., 32(9): 1172-76.
  4. Frost L and Vestergaard P (2010): Alcohol and risk of atrial fibrillation or flutter: a cohort study. Archives of Internal Medicine, 164(18): 1993-1998.
  5. Heeringa J, Kors JA, Hofman A, van Rooij FJ and Witteman JC. (2010): Cigarette smoking and risk of atrial fibrillation: the Rotterdam Study. American Heart Journal, 156(6): 1163-1169.
  6. Jaakkola S, Lip GY, Biancari F, Nuotio I, Hartikainen JE, Ylitalo A and Airaksinen KJ. (2017): Predicting unsuccessful electrical cardioversion for acute atrial fibrillation (from the AF-CVS Score). American Journal of Cardiology, 119(5): 749-752.
  7. January CT, Wann LS, Calkins H, Chen LY and Cigarroa JE. (2019): 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology, 74(1): 104-132.
  8. Kannel WB, Wolf PA, Benjamin EJ and Levy D. (2010): Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. American Journal of Cardiology, 82(7): 2-9.
  9. Kinoshita M, Herges RM, Hodge DO, Friedman L, Ammash NM, Bruce CJ, Somers V, Malouf JF, Askelin J, Gilles JA and Gersh BJ. (2010): Role of smoking in the recurrence of atrial arrhythmias after cardioversion. American Journal of Cardiology, 104(5): 678-682.

10. Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U, Ravens U, Samol A, Steinbeck G, Treszl A and Wegscheider K. (2012): Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. The Lancet, 380(9838): 238-246.

11. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B and Castella M. (2016): 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-Thoracic Surgery, 50(5): 1-88.

12. Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ and Smith CJ. (2014): Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke, 45(2): 520-526.

13. Kotecha D, Holmes J, Krum H, Altman DG and Manzano L. (2014): Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. The Lancet, 384(9961): 2235-2243.

14. Lee SH, Kim JB, Cho WC, Chung CH, Jung SH, Choo SJ and Lee JW (2011): The influence of age on atrial fibrillation recurrence after the maze procedure in patients with giant left atrium. The Journal of Thoracic and Cardiovascular Surgery, 141(4): 1015-1019.

15. Ma X, Zhang X and Guo W. (2011): Factors to predict recurrence of atrial fibrillation in patients with hypertension. Clinical Cardiology: An International Indexed and Peer-Reviewed Journal for Advances in the Treatment of Cardiovascular Disease, 32(5): 264-268.

16. Movahed MR, Hashemzadeh M and Jamal MM. (2011): Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. International Journal of Cardiology, 105(3): 315-318.

17. Stewart S, Hart CL, Hole DJ and McMurray JJ. (2012): A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. The American Journal of Medicine, 113(5): 359-364.

 

التنبوء بفشل الصدمات الکهربية القلبية في علاج الرجفان الأذيني ((AF-CVS عن طريق إستخدام مجموع نقاط

حمدي صبحي رمضان العدوى, عبد الحليم محمد أبو المجد, منصور محمد سلام

قسم أمراض القلب والأوعية الدموية، کلية الطب, جامعة الازهر

E-mail: hamdiramadan_99@gmail.com

خلفية البحث: يبقي مرض الرجفان الأذيني واحدا من أکبر أسباب جلطات الدم، وقصوروظائف القلب، والموت المفاجئ. ويضاعف مرض الرجفان الأذيني من خطورة أسباب الوفيات في السيدات, کما يزيد منها في الرجال الي مرة ونصف. ويعوق هذا المرض حياة مرضاه فهناک مايقرب من 10-40% من مرضي الرجفان الأذيني يترددون علي المستشفيات سنويا لهذا السبب فقط. وعلاج الصدمات الکهربية القلبية يعد علاجا أساسيا في حالات الرجفان الأذيني الحاد ولهذا, فإن تعريف الحالات ذات القابلية العالية لفشل هذه الصدمات الکهربية أو العرضة المبکرة لتکرار هذه النوبة من الرجفان الأذيني يبقي ذات أهمية کبيرة في اتخاذ القرار الطبي المناسب.

الهدف من البحث: الوصول إلي أداة مطابقة لتعريف الحالات الأکثر عرضة لعدم نجاح الصدمات الکهربية القلبية في علاج حالات الرجفان الأذيني الحاد.

المرضى وطرق البحث: هذه دراسة جماعية أجريت بين مارس 2018 ومارس 2019. وقد تم تسجيل 100 مريض متتالي تم قبولهم في مستشفي الحسين، جامعة الأزهر تعرضوا للرجفان الأذيني الحاد الذي يتطلب إصدارًا کهربائيًا مباشرًا. (نسخة کهربائية DC). بعد الحصول على موافقة مستنيرة من کل مريض بعد شرح کامل لأهداف البحث والغرض من هذه الدراسة.

نتائج البحث: حدث تکرار لحالة الرجفان الأذيني الحاد فى 37 مريض, بينما 63 مريض لم يحدث لهم أى تکرار للرجفان الأذينى بعد شهر من العلاج بالصدمات الکهربية. وقد وجدنا فارقاً بين مجموع النقاط للحالات التى لم تظهر تکرار للرجفان ومجموع النقاط للحالات التى أظهرت تکراراً. وکان هذا الفارق ذو دلالة احصائية حيث أن مجموع النقاط للحالات التى نجح فيها علاج الصدمات الکهربية فى منع تکرار الرجفان الاذينى اقل من مجموع النقاط للحالات التى فشل فيها العلاج بالصدمات الکهربية. وعلي ذلک، فإن مجموع النقاط يمکن أن يستخدم فى التنبوء بنجاح العلاج بالصدمات الکهربية من عدمه. وقد أظهر مجموع النقاط فعالية تشخيص بنسبة حساسية 84% تقريبا, ونسبة خصوصية 63%, وکانت القيمة التنبؤية الإيجابية 61%تقريبا, والقيمة التنبؤية السلبية 88% تقريبا, ودقة مجموع النقاط کانت بنسبة 74%.

الإستنتاج: يمکن التنبوء بمخاطر النتيجة غير الناجحة لتقويم نظم القلب الکهربائي باستخدام خمسة متغيرات سريرية بسيطة: العمر، المرة الأولى الرجفان الأذيني، قصور القلب، أمراض الأوعية الدموية، مدة قصيرة من الرجفان الأذيني السابق في غضون شهر واحد قبل إصدار القلب الکهربائي.

الکلمات الدالة: الصدمات الکهربائية القلبية، الرجفان الأذينى الحاد، مجموع نقاط ايه اف سى فى اس.

  1. REFERENCES

    1. Amin A, Houmsse A, Ishola A, Tyler J and Houmsse M. (2016): The current approach of atrial fibrillation management. Avicenna Journal of Medicine, 6(1):8-16.
    2. Berruezo A, Tamborero D, Mont L, Benito B and Tolosana JM. (2011): Pre-procedural predictors of atrial fibrillation recurrence after circumferential pulmonary vein ablation. European Heart Journal, 28(7): 836-841.
    3. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S and  Van Gelder IC (2011): Guidelines for the management of atrial fibrillation The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J., 32(9): 1172-76.
    4. Frost L and Vestergaard P (2010): Alcohol and risk of atrial fibrillation or flutter: a cohort study. Archives of Internal Medicine, 164(18): 1993-1998.
    5. Heeringa J, Kors JA, Hofman A, van Rooij FJ and Witteman JC. (2010): Cigarette smoking and risk of atrial fibrillation: the Rotterdam Study. American Heart Journal, 156(6): 1163-1169.
    6. Jaakkola S, Lip GY, Biancari F, Nuotio I, Hartikainen JE, Ylitalo A and Airaksinen KJ. (2017): Predicting unsuccessful electrical cardioversion for acute atrial fibrillation (from the AF-CVS Score). American Journal of Cardiology, 119(5): 749-752.
    7. January CT, Wann LS, Calkins H, Chen LY and Cigarroa JE. (2019): 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Journal of the American College of Cardiology, 74(1): 104-132.
    8. Kannel WB, Wolf PA, Benjamin EJ and Levy D. (2010): Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. American Journal of Cardiology, 82(7): 2-9.
    9. Kinoshita M, Herges RM, Hodge DO, Friedman L, Ammash NM, Bruce CJ, Somers V, Malouf JF, Askelin J, Gilles JA and Gersh BJ. (2010): Role of smoking in the recurrence of atrial arrhythmias after cardioversion. American Journal of Cardiology, 104(5): 678-682.

    10. Kirchhof P, Andresen D, Bosch R, Borggrefe M, Meinertz T, Parade U, Ravens U, Samol A, Steinbeck G, Treszl A and Wegscheider K. (2012): Short-term versus long-term antiarrhythmic drug treatment after cardioversion of atrial fibrillation (Flec-SL): a prospective, randomised, open-label, blinded endpoint assessment trial. The Lancet, 380(9838): 238-246.

    11. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B and Castella M. (2016): 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. European Journal of Cardio-Thoracic Surgery, 50(5): 1-88.

    12. Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ and Smith CJ. (2014): Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. Stroke, 45(2): 520-526.

    13. Kotecha D, Holmes J, Krum H, Altman DG and Manzano L. (2014): Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. The Lancet, 384(9961): 2235-2243.

    14. Lee SH, Kim JB, Cho WC, Chung CH, Jung SH, Choo SJ and Lee JW (2011): The influence of age on atrial fibrillation recurrence after the maze procedure in patients with giant left atrium. The Journal of Thoracic and Cardiovascular Surgery, 141(4): 1015-1019.

    15. Ma X, Zhang X and Guo W. (2011): Factors to predict recurrence of atrial fibrillation in patients with hypertension. Clinical Cardiology: An International Indexed and Peer-Reviewed Journal for Advances in the Treatment of Cardiovascular Disease, 32(5): 264-268.

    16. Movahed MR, Hashemzadeh M and Jamal MM. (2011): Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. International Journal of Cardiology, 105(3): 315-318.

    17. Stewart S, Hart CL, Hole DJ and McMurray JJ. (2012): A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. The American Journal of Medicine, 113(5): 359-364.